Mahamaya Lifesciences to Reschedule Utilization of Unutilized IPO Proceeds

Key Highlights

• Mahamaya Lifesciences to reschedule the utilization of unutilized IPO proceeds in subsequent fiscal years up to March 31, 2028.
• The decision was made due to various project execution factors and the need to incorporate enhancements in plant configuration, machinery specifications, and civil and structural components.
• The company assures that there is no change in the project scope, intended capacity, or overall utilization of IPO proceeds.
• Unutilized IPO proceeds are currently maintained in compliance with applicable laws and are temporarily parked in permitted interest-bearing instruments pending deployment.
• The company shall continue to disclose the utilization of IPO proceeds in accordance with Regulation 32 of SEBI LODR Regulations.